Navigation Links
American Brain Tumor Association Supports $2 Million Glioblastoma Research Project
Date:9/3/2014

Chicago, IL (PRWEB) September 03, 2014

The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world.

Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly malignant tumor’s octopus-like tentacles make it difficult to remove completely during surgery, and with current treatments, median survival is about 14.6 months. A small percentage of patients experience better outcomes and become long-term survivors.

The Brain Tumor Funders’ Collaborative—a strategic partnership among advocacy organizations like the ABTA and private philanthropic groups—initiated a call for research proposals to investigate why only a minority of glioblastoma (GBM) patients achieves long-term survival.

The researchers aim to understand the basis for long-term survival with glioblastoma by comprehensively studying patient histories, tumor characteristics at the molecular genetic level, and effects of treatment. To do this, the researchers identified a large group of more than 300 patients who have survived glioblastoma for more than five years. Understanding the shared characteristics of long-term surviving patients allows for better understanding of the biology of this deadly disease, and will ultimately lead to improved treatments for all patients.

“We are proud to partner in this global initiative and support collaborative science which is vital to furthering our understanding of the characteristics of survivors and potentially uncover new research directions,” said Elizabeth M. Wilson, MNA, ABTA president and CEO. “Collaborations such as these support the ABTA’s mission to advance the understanding and treatment of brain tumors in an effort to improve, extend and ultimately save lives.”

The recipient of the BTFC grant is a research consortium led by the European Organization for Research and Treatment of Cancer (EORTC) and the Brain Tumor Center at the University Hospital in Zurich. The consortium, comprised of more than 20 Neuro-oncology Centers of Excellence across the globe, include researchers in Europe, the United States and Canada.

The project will be managed by Michael Weller, M.D., of the University Hospital Zurich and Patrick Yung Wen, M.D. of the Dana Farber Cancer Institute, in support of the EORTC.

About the American Brain Tumor Association
Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing information and education on all tumor types and all age groups. For more information, visit http://www.abta.org or call 800-886-ABTA (2282).

About the Brain Tumor Funders’ Collaborative
Inaugurated in 2003, the Brain Tumor Funders’ Collaborative (BTFC) is a strategic partnership among private philanthropic and advocacy organizations in the US and Canada to pool their resources and focus their research dollars toward advancing the understanding and treatment of brain tumors. The five members of the BTFC are: the American Brain Tumor Association, Brain Tumour Foundation of Canada, Children’s Brain Tumor Foundation, James S. McDonnell Foundation, and the Sontag Foundation.

About the European Organisation for Research and Treatment of Cancer
The European Organisation for Research and Treatment of Cancer (EORTC) is an International non-profit association (AISBL) founded in 1962 and established under the laws of Belgium. The aims of EORTC are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. EORTC is both multinational and multidisciplinary, and the EORTC network comprises over 300 hospitals and cancer centers in over 30 countries, including about 2,500 collaborators from all disciplines involved in cancer treatment and research. The primary aim of the EORTC Brain Tumor Group (BTG) is to conduct, develop, coordinate, and stimulate clinical and translational research for the treatment of brain tumors and metastases.

# # #

Read the full story at http://www.prweb.com/releases/2014/09/prweb12139518.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program
2. American Pain Society Returns with REMS Training at PAINWeek 2014 in Las Vegas
3. Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference
4. Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans
5. Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing
6. Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5%
7. North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia
8. As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture
9. North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX
10. There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job
11. American Telemedicine Association Issues Clinical Guidelines for Telepathology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of ... improve smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the ... to learn more about the options currently available to them and which ones might ...
(Date:4/29/2016)... , ... April 29, 2016 , ... For those who ... the meal to miss. That was among the many new lifestyle diet tips offered ... recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 TapImmune,Inc. (TPIV), a ... and gene-based immunotherapeutics and vaccines for the treatment of cancer ... the 3rd Annual Growth Capital Expo to be ... at Caesars Palace in Las Vegas, Nevada.  The Company ... 4 th by Dr. John N. Bonfiglio ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology: